EGFR and neoplasm: Since the identical EGFR mutation patterns occurred in the squamous cell carcinomatous and the adenocarcinomatous components of ASC, It may be the proportion of two tumor components in EGFR mutant ASC patients that determines the efficacy of EGFR-TKI in EGFR mutant ASC patients.